Page last updated: 2024-11-06

fat red 7b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fat red 7B: lipophilic dye [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID61396
CHEBI ID82537
SCHEMBL ID39613
SCHEMBL ID11876264
SCHEMBL ID11876269
MeSH IDM0134811

Synonyms (78)

Synonym
[(phenyl[azo-4-(phenylazo)]]-1-ethylamino-2-naphthalene
1-[4-(phenylazo)-phenylazo]-2-ethylaminonaphthalene
typogen carmine
n-ethyl-1-[[4-(phenylazo)phenyl]azo]-2-naphthylamine
c.i. 26,050
c.i. 26050
lacquer red v3b
hexatype carmine b
sudanrot 7b
fat red 7b
c.i. solvent red 19
2-naphthalenamine, n-ethyl-1-[[4-(phenylazo)phenyl]azo]-
ceres red 7b
organol bordeaux b
nsc326202
special blue x-2137
n-ethyl-1-[[p-(phenylazo)phenyl]azo]-2-naphthalenamine
sudan red 7b
6368-72-5
2-naphthylamine, n-ethyl-1-[[p-(phenylazo)phenyl]azo]-
wln: l66j bnunr dnunr&& cm2
solvent red 019
solvent red 19
nsc-326202
n-ethyl-1-((p-(phenylazo)phenyl)azo)-2-naphthalenamine
nsc 326202
special blue x 2137
1-(4-phenylazo-phenylazo)-2-ethylaminonaphthalene
sudan 7b
n-ethyl-1-(4-(phenylazo)phenylazo)-2-naphthylamine
2-naphthylamine, n-ethyl-1-((p-(phenylazo)phenyl)azo)-
brn 3534323
cerven rozpoustedlova 19 [czech]
(phenylazo-4-phenylazo)-1-ethylamino-2-naphthalene
einecs 228-862-5
2-naphthalenamine, n-ethyl-1-((4-(phenylazo)phenyl)azo)-
n-ethyl-1-((4-(phenylazo)phenyl)azo)-2-naphthylamine
sudan red 7b, dye content 95 %
sudan red 7b, for microscopy (bot., hist.)
n-ethyl-1-[(4-phenyldiazenylphenyl)diazenyl]naphthalen-2-amine
O0096
n-ethyl-1-[2-[4-(2-phenyldiazenyl)phenyl]diazenyl]-2-naphthalenamine
C19529
AKOS024348915
unii-8quh39y06p
cerven rozpoustedlova 19
fat red
2-naphthalenamine, n-ethyl-1-(2-(4-(2-phenyldiazenyl)phenyl)diazenyl)-
8quh39y06p ,
4-16-00-00556 (beilstein handbook reference)
FT-0636119
2-naphthalenamine, n-ethyl-1-[2-[4-(2-phenyldiazenyl)phenyl]diazenyl]-
SCHEMBL39613
CHEBI:82537
SCHEMBL11876264
SCHEMBL11876269
DTXSID4064266
fat red bluish
n-ethyl-1-((4-[phenyldiazenyl]phenyl)diazenyl)-2-naphthalenamine #
1-(4-(phenylazo)-phenylazo)-2-ethylaminonaphthalene
(phenyl(azo-4-(phenylazo))-1-ethylamino-2-naphthalene
VKWNTWQXVLKCSG-ZDXBJJIESA-N
n-ethyl-1-((4-(phenyldiazenyl)phenyl)diazenyl)naphthalen-2-amine
mfcd00003904
sudan red 460
sudan red 462
lacquer red v 3b nsc
sudan red 7b [iarc]
n-ethyl-1-(2-(4-(2-phenyldiazenyl)phenyl)diazenyl)-2-naphthalenamine
ci 26050
sudan red 7b, analytical standard
n-ethyl-1-[(1e)-2-{4-[(1e)-2-phenyldiazen-1-yl]phenyl}diazen-1-yl]naphthalen-2-amine
n-ethyl-1-((e)-(4-((e)-phenyldiazenyl)phenyl)diazenyl)naphthalen-2-amine
Q27889956
sudan red 7b 100 microg/ml in acetonitrile
Q6518814
H12056
AS-76183

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The pellets are capable of transfering lipophilic compounds into the aqueous phase and have a high potential to increase the bioavailability of lipophilic drugs."( Preparation and characterization of a self-emulsifying pellet formulation.
Abdalla, A; Mäder, K, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (12.50)18.7374
1990's3 (18.75)18.2507
2000's6 (37.50)29.6817
2010's4 (25.00)24.3611
2020's1 (6.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.10 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (6.25%)5.53%
Reviews1 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]